Citi highlights the strong financial performance of Firdapse, projecting that the drug will surpass $550 million in peak U.S. sales by 2034. This forecast is supported by Catalyst's consistent track record of delivering double-digit year-over-year growth in Firdapse revenues since the drug received FDA approval. The settlement with Teva thus reinforces the drug's potential for continued revenue growth and enhances Catalyst's financial outlook.
For deeper insights into Catalyst's financial health and growth prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, covering over 1,400 US stocks with expert analysis and actionable intelligence. For deeper insights into Catalyst's financial health and growth prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, covering over 1,400 US stocks with expert analysis and actionable intelligence.
Citi highlights the strong financial performance of Firdapse, projecting that the drug will surpass $550 million in peak U.S. sales by 2034. This forecast is supported by Catalyst's consistent track record of delivering double-digit year-over-year growth in Firdapse revenues since the drug received FDA approval.
The settlement with Teva thus reinforces the drug's potential for continued revenue growth and enhances Catalyst's financial outlook. For deeper insights into Catalyst's financial health and growth prospects, investors can access the detailed Pro Research Report available exclusively on InvestingPro, covering over 1,400 US stocks with expert analysis and actionable intelligence.
Citi highlights the strong financial performance of Firdapse, projecting that the drug will surpass $550 million in peak U.S. sales by 2034. This forecast is supported by Catalyst's consistent track record of delivering double-digit year-over-year growth in Firdapse revenues since the drug received FDA approval. The settlement with Teva thus reinforces the drug's potential for continued revenue growth and enhances Catalyst's financial outlook.
In other recent news, Catalyst Pharmaceuticals (NASDAQ:CPRX) reported a notable increase in its Q3 2024 revenues, primarily driven by solid sales of FIRDAPSE and AGAMREE. The company's total revenues rose to $128.7 million, a 25.3% increase from the previous year. Furthermore, Catalyst Pharma revised its full-year revenue guidance upwards to between $475 million and $485 million, indicating its confidence in sustained product demand.
FIRDAPSE generated $79.3 million in net revenues, up 19.7%, while AGAMREE contributed $15 million in its second quarter after launch. The company also maintains a robust cash position, with $442.3 million in cash and cash equivalents.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.